On Tuesday, shares in Missouri headquartered Cerner Corp. recorded a trading volume of 1.91 million shares. The stock ended at $48.50, declining 0.39% from the last trading session. The Company's shares are trading below their 50-day moving average by 8.65%. Furthermore, shares of Cerner, which designs, develops, markets, installs, hosts, and supports health care information technology, health care devices, hardware, and content solutions for health care organizations and consumers in the US and internationally, have a Relative Strength Index (RSI) of 39.09.
On December 13th, 2016, research firm Morgan Stanley downgraded the Company's stock rating from 'Equal-Weight' to 'Underweight'.
On December 16th, 2016, the Unified Government of Wyandotte County and Kansas City, Kansas, in collaboration with Cerner, and the University of Kansas Hospital announced the opening of the Road to Wellness Health Center. Cerner's management of the health center will include primary care, health education through coaching, and prevention and wellness screening services centered on the preferences and risks of each plan member. CERN complete research report is just a click away at:
California headquartered Veeva Systems Inc.'s stock finished yesterday's session 0.26% higher at $43.03, with a total trading volume of 1.17 million shares. The Company's shares have gained 3.56% in the last one month, 3.12% over the previous three months, and 49.15% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.50% and 21.96%, respectively. Furthermore, shares of Veeva Systems, which provides industry cloud software and data solutions for the life sciences industry in North America, the European Union, the Asia Pacific, and internationally, have an RSI of 53.78.
On November 23rd, 2016, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $45 to $48.
On December 12th, 2016, Veeva Systems announced that Advanced Health Media, HealthSTAR Communications, MedForce, Physicians World, and Vector Health are leveraging the power of Veeva CRM Events Management to offer life sciences customers a full, end-to-end solution for enterprise-wide planning and execution of live and virtual events. The complimentary report on VEEV can be downloaded at:
At the closing bell on Tuesday, shares in West Palm Beach, Florida headquartered Rennova Health Inc. rose 1.44%, ending the day at $0.09. The stock recorded a trading volume of 4.91 million shares, which was above its three months average volume of 2.49 million shares. The Company's shares have advanced 2.92% in the last one month. The stock is trading 28.87% below its 50-day moving average. Moreover, shares of Rennova Health, which provides diagnostics and supportive software solutions to healthcare providers, have an RSI of 42.79.
On November 19th, 2016, Rennova Health announced the pricing of 12,350 shares of its Series H Convertible Preferred Stock at a per share price of $1,000. The Series H Preferred Stock has a stated value of $1,000 per share with each share convertible into 11,111 shares of common stock, at a conversion price of $0.09 per share. The gross proceeds from this offering are expected to be approximately $12,350,000 before deducting underwriting discounts and commissions and other estimated offering expenses. Sign up for your complimentary report on RNVA at:
Draper, Utah headquartered HealthEquity Inc.'s stock ended the day 0.25% higher at $40.29, with a total trading volume of 397,910 shares. The Company's shares have gained 11.30% over the previous three months and 60.71% on an YTD basis. The stock is trading 4.95% above its 50-day moving average and 29.83% above its 200-day moving average. Additionally, shares of HealthEquity, which provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the US, have an RSI of 47.38.
On December 7th, 2016, HealthEquity launched Balance Booster™. This new feature, available to employers offering HealthEquity Health savings account, provides members advance access to funds. Account holders with access to this feature no longer have to worry about incurring medical costs early in the year before their HSA balance has grown.
On December 13th, 2016, research firm Chardan Capital Markets initiated a 'Buy' rating on the Company's stock, issuing a target price of $50 per share. Download the research report for free on HQY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA